Tag:
Ramius
Latest Headlines
Latest Headlines
Ramius completes Cypress Bioscience buy
New York investors have completed their acquisition of San Diego drugmaker Cypress Bioscience, which had been a publicly held company, a spokesman for the new owners said Thursday. The acquisition by
Cypress wrangles $255M buyout deal with Ramius
Sometimes, it pays to sit tight. After months of wrangling over a price, the investor group Ramius has finally landed a deal to acquire San Diego-based Cypress Bioscience ( $CYPB ) for $255 million--a
Ramius sweetens offer for Cypress
Hedge fund operator Ramius V&O Acquisition LLC has sent a letter to the Cypress Bioscience board stating its willingness to acquire all of biotech's outstanding common stock for $5.50 per share.
Cypress still unimpressed by Ramius takeover offer
The board of Cypress Bioscience has unanimously rejected the unsolicited tender offer by Ramius V&O Acquisition LLC to purchase all of the outstanding shares of the company for $4.25 per share in
Ramius raises offer for Cypress
Investor manager Ramius is going to the stockholders in its bid to take over Cypress Biosciences, increasing its offer to $4.25 per share in cash. The move comes roughly two months after Ramius
Under fire, Cypress pledges $33M to acquire CNS programs
Cypress Bioscience isn't letting any unwelcome attention from hedge fund operator Ramius stop it from doing new deals to beef up its CNS pipeline. Just a day after Ramius let loose with another
Cypress shoots down Ramius offer--again
The tussle between Ramius and Cypress Bioscience continues today with the biotech responding to a Ramius offer dated Aug. 11 . In its letter, Cypress rejects Ramius' latest offer, stating "it would be
Ramius tempts Cypress shareholders with sweetened offer
Ramius isn't taking 'no' for an answer after Cypress Bioscience's board opted to reject its buyout offer. In a carefully worded letter, which the hedge fund operator was equally careful to make
Cypress rebuffs Ramius buyout offer
Cypress Bioscience has rejected a $154 million buyout proposal floated by investor manager Ramius last month. "After carefully and thoroughly reviewing the contents of your proposal and with the
Ramius looks to buy out Cypress
Shares of Cypress Bioscience rallied Monday on word that investor manager Ramius, which has had some problems with the way the biotech has been run, had offered to buy all outstanding shares of the
